ACAD
31.856
-0.544
-1.679%
AEMD
5.04
+0.22
+4.56%
APRI
0.555
+0.013
+2.399%
ARNA
1.75
-0.02
-1.13%
ATEC
0.245
+0.007
+2.812%
CNAT
2.85
0.00
0.00%
CRXM
0.19
0.00
0.00%
CYTX
0.318
-0.022
-6.471%
DXCM
62.69
-3.27
-4.96%
GNMK
5.9
-0.17
-2.80%
HALO
10.67
-0.17
-1.57%
ILMN
132.493
-3.257
-2.399%
INNV
0.087
-0.009
-9.375%
INO
10.42
-0.76
-6.7988%
ISCO
4
+0.15
+3.90%
ISIS
57.56
0.00
0.00%
LGND
119.573
-3.547
-2.8813%
LPTN
0.242
+0.00
+0.0413%
MBVX
0.7
-0.02
-3.42%
MEIP
1.42
+0.02
+1.43%
MNOV
6.853
-0.127
-1.819%
MRTX
20.2
-0.84
-3.99%
MSTX
0.3
-0.001
-0.3323%
NBIX
45.96
-0.94
-2.00%
NUVA
52.365
-0.735
-1.3844%
ONCS
1.98
+0.03
+1.54%
ONVO
2.81
+0.06
+2.18%
OREX
0.45
-0.016
-3.5148%
OTIC
14.02
-0.6
-4.10%
QDEL
17.24
-0.44
-2.49%
RCPT
231.96
0.00
0.00%
RGLS
5.81
-0.35
-5.6834%
RMD
55.545
-0.955
-1.690%
SCIE
0.003
0.00
-3.3333%
SPHS
1.178
-0.022
-1.833%
SRNE
6.7
-0.2
-2.90%
TROV
4.08
-0.08
-1.92%
VICL
0.38
-0.015
-3.8481%
VOLC
18
0.00
0.00%
ZGNX
10.31
-0.32
-3.01%
ACAD
31.856
-0.544
-1.679%
AEMD
5.04
+0.22
+4.56%
APRI
0.555
+0.013
+2.399%
ARNA
1.75
-0.02
-1.13%
ATEC
0.245
+0.007
+2.812%
CNAT
2.85
0.00
0.00%
CRXM
0.19
0.00
0.00%
CYTX
0.318
-0.022
-6.471%
DXCM
62.69
-3.27
-4.96%
GNMK
5.9
-0.17
-2.80%
HALO
10.67
-0.17
-1.57%
ILMN
132.493
-3.257
-2.399%
INNV
0.087
-0.009
-9.375%
INO
10.42
-0.76
-6.7988%
ISCO
4
+0.15
+3.90%
ISIS
57.56
0.00
0.00%
LGND
119.573
-3.547
-2.8813%
LPTN
0.242
+0.00
+0.0413%
MBVX
0.7
-0.02
-3.42%
MEIP
1.42
+0.02
+1.43%
MNOV
6.853
-0.127
-1.819%
MRTX
20.2
-0.84
-3.99%
MSTX
0.3
-0.001
-0.3323%
NBIX
45.96
-0.94
-2.00%
NUVA
52.365
-0.735
-1.3844%
ONCS
1.98
+0.03
+1.54%
ONVO
2.81
+0.06
+2.18%
OREX
0.45
-0.016
-3.5148%
OTIC
14.02
-0.6
-4.10%
QDEL
17.24
-0.44
-2.49%
RCPT
231.96
0.00
0.00%
RGLS
5.81
-0.35
-5.6834%
RMD
55.545
-0.955
-1.690%
SCIE
0.003
0.00
-3.3333%
SPHS
1.178
-0.022
-1.833%
SRNE
6.7
-0.2
-2.90%
TROV
4.08
-0.08
-1.92%
VICL
0.38
-0.015
-3.8481%
VOLC
18
0.00
0.00%
ZGNX
10.31
-0.32
-3.01%
Home » SDBN Blog

Bioethics in Drug Development: BIO2014

Submitted by on June 24, 2014 – 6:52 am

Consider a case where a patient has a disease with high mortality and no effective treatment available. A new experimental drug is now being tested in a clinical trial. However, this is a randomized clinical trial, which means that it will have a treatment group and a placebo group (that does not get the actual drug).

via Bioethics in Drug Development: BIO2014.

Tags:

Leave a comment!

Add your comment below, or trackback from your own site. You can also Comments Feed via RSS.

Be nice. Keep it clean. Stay on topic. No spam.

You can use these tags:

<a href="" title="" rel=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong> 

This is a Gravatar-enabled weblog. To get your own globally-recognized-avatar, please register at Gravatar.

Please prove you\'re human, solve this: *